Abstract
We compared the prevalence of key pfmdr1 alleles between pretreatment Plasmodium falciparum parasite isolates and parasites that emerged after treatment of uncomplicated malaria in a longitudinal cohort of Ugandan children. The pfmdr1 86N, 184F, and 1246D alleles were selected after treatment with artemether-lumefantrine, but not after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine. Remarkably, selection persisted in infections presenting up to about 60 days after treatment with artemether-lumefantrine. Thus, parasites selected for decreased drug sensitivity can appear long after predicted exposure to antimalarial drugs. Continued surveillance of the clinical efficacy and in vitro activity of new combination therapies is warranted.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Alleles
-
Amodiaquine / administration & dosage
-
Amodiaquine / pharmacology
-
Antimalarials / pharmacology*
-
Antimalarials / therapeutic use
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins / administration & dosage
-
Artemisinins / pharmacology
-
Child
-
Child, Preschool
-
Drug Combinations
-
Drug Resistance / genetics*
-
Drug Therapy, Combination
-
Ethanolamines / administration & dosage
-
Ethanolamines / pharmacology
-
Female
-
Fluorenes / administration & dosage
-
Fluorenes / pharmacology
-
Humans
-
Infant
-
Longitudinal Studies
-
Malaria, Falciparum / drug therapy*
-
Malaria, Falciparum / parasitology*
-
Male
-
Plasmodium falciparum / drug effects*
-
Plasmodium falciparum / genetics*
-
Polymorphism, Genetic*
-
Pyrimethamine / administration & dosage
-
Pyrimethamine / pharmacology
-
Sulfadoxine / administration & dosage
-
Sulfadoxine / pharmacology
-
Time Factors
-
Uganda
Substances
-
Antimalarials
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins
-
Drug Combinations
-
Ethanolamines
-
Fluorenes
-
amodiaquine, artesunate drug combination
-
Amodiaquine
-
Sulfadoxine
-
Pyrimethamine